Candidiasis Therapeutics Market Size, Analysis, Trends And Strategies 2024-2033

"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Candidiasis Therapeutics Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $3.66 billion In 2028 At A CAGR Of 3.5% :

The candidiasis therapeutics market size has grown steadily in recent years. It will grow from $3.06 billion in 2023 to $3.19 billion in 2024 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to increased incidence of candidiasis, antibiotic use and resistance, hospital-acquired infections, shift in fungal resistance patterns, awareness and education programs..

The candidiasis therapeutics market size is expected to see steady growth in the next few years. It will grow to $3.66 billion in 2028 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to precision medicine approaches, global antifungal stewardship programs, increasing prevalence of candida auris, global efforts against antifungal resistance.. Major trends in the forecast period include advancements in drug delivery technologies, telemedicine and remote patient monitoring, patient-centric care, combination therapies, collaborative research initiatives..

Request A Sample Of This Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13182&type=smp

Candidiasis Therapeutics Market Major Segments

Key Driver - Rising Fungal Infection Rates Fueling Growth In The Candidiasis Therapeutics Market

The growing incidence of fungal infections is expected to propel the growth of the candidiasis therapeutics market going forward. Fungal infections are illnesses caused by various fungi that can affect the skin, mucous membranes, and internal organs in humans. The rising number of individuals with compromised immune systems and individuals with fungal infections increases the susceptibility to candidiasis, creating opportunities for manufacturers to develop and supply specialized and more effective antifungal drugs that target the underlying fungal pathogens, relieve symptoms, prevent complications, promote patient recovery, reduce the spread of Candida infections within healthcare facilities, and contribute to better patient outcomes. For instance, in July 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, fungal infection-related hospitalizations reached a total of 59,212 by 2021, with the rate of these hospitalizations increasing from 25.0 in 2020 to 26.8 in 2021 per 10,000 hospitalizations, with an average annual increase of 8.5%. Moreover, the fungal hospitalizations with the highest death rates among COVID-19 patients were linked to aspergillosis (57.6%), invasive candidiasis (55.4%), mucormycosis (44.7%), and unspecified mycoses (59.0%). Therefore, the growing incidence of fungal infections will drive the growth of the candidiasis therapeutics market.

Customise This Report As Per Your Requirements -
https://www.thebusinessresearchcompany.com/Customise?id=13182&type=smp

Prominent Trend - Innovative Drugs Transforming The Candidiasis Treatment

Major companies operating in the candidiasis therapeutics market are developing innovative drugs such as BREXAFEMME (ibrexafungerp tablets) to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in adult women. BREXAFEMME (ibrexafungerp tablets) is an oral, non-azole medication for the treatment of vulvovaginal candidiasis (VVC) and the reduction of the incidence of recurrent vulvovaginal candidiasis (RVVC), also known as chronic yeast infections. For instance, in December 2022, Scynexis Inc., a US-based pharmaceutical company, received the US Food and Drug Administration (FDA) approval for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), also known as chronic yeast infections. BREXAFEMME works by blocking the growth of Candida albicans, the fungus that causes VVC. Moreover, it is a safe and effective treatment option for vulvovaginal candidiasis (VVC). It is also available only by prescription, with a recommended dose of one 150-mg capsule taken orally once daily for one day.

Candidiasis Therapeutics Market Players
Major companies operating in the candidiasis therapeutics market report are Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc., GSK plc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Bruker Corporation, Lupin Limited, Galapagos NV, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Pacgen Life Science Corporation, Cidara Therapeutics Inc., Ablynx NV, Amplyx Pharmaceuticals Inc., NovaDigm Therapeutics Inc., SCYNEXIS Inc., Medivir AB, Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc.

View The Full Report Here -
https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the candidiasis therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candidiasis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Candidiasis Therapeutics Market Report Structure
3. Candidiasis Therapeutics Market Trends And Strategies
4. Candidiasis Therapeutics Market - Macro Economic Scenario
5. Candidiasis Therapeutics Market Size And Growth
…..
27. Candidiasis Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.